Holen Sie sich die Stockscreener-App
33.51
6.66%
-2.39
Handel nachbörslich:
33.59
0.08
+0.24%
Schlusskurs vom Vortag:
$35.90
Offen:
$35.13
24-Stunden-Volumen:
26,830
Relative Volume:
0.72
Marktkapitalisierung:
$204.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-14.57
EPS:
-2.3
Netto-Cashflow:
$-6.82M
1W Leistung:
-17.56%
1M Leistung:
-9.11%
6M Leistung:
-25.00%
1J Leistung:
+1,285%
1-Tages-Spanne:
$32.01
$36.06
1-Wochen-Bereich:
$30.51
$41.70
52-Wochen-Spanne:
$2.15
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Vergleichen Sie MNPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
33.51 | 219.54M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
Does Monopar Therapeutics Inc. fit your quant trading modelJuly 2025 Short Interest & Weekly Chart Analysis and Guides - Newser
Using Bollinger Bands to evaluate Monopar Therapeutics Inc.Quarterly Profit Review & Stock Portfolio Risk Control - Newser
Monopar Therapeutics Inc. stock trend forecast2025 Market Trends & Expert Curated Trade Ideas - Newser
How to escape a deep drawdown in Monopar Therapeutics Inc.Day Trade & Free Verified High Yield Trade Plans - Newser
Monopar Therapeutics Inc. stock volume spike explained2025 Geopolitical Influence & Weekly Breakout Watchlists - Newser
How to use a screener to detect Monopar Therapeutics Inc. breakoutsRate Cut & Long-Term Capital Growth Strategies - Newser
Will Monopar Therapeutics Inc. outperform the market2025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
Will Monopar Therapeutics Inc. price bounce be sustainableTrade Signal Summary & Expert Approved Momentum Ideas - Newser
Monopar Therapeutics Reports Increased R&D Expenses - TipRanks
What makes Monopar Therapeutics Inc. stock price move sharplySmart Trade Mapping with Entry Details - Newser
Monopar Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingTop Gaining Picks With Entry Signals Identified - 선데이타임즈
When is the best time to buy Monopar Therapeutics Inc. stock2025 Trade Ideas & Weekly Top Performers Watchlists - Newser
Monopar Therapeutics Inc. Reports Q2 2025 Financial Results and Progress on ALXN1840 and MNPR-101 Clinical Trials - Quiver Quantitative
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics SEC 10-Q Report - TradingView
Monopar Q2 Earnings: $53.3M Cash Position Funds Wilson Disease Drug NDA | MNPR Stock News - Stock Titan
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Will Monopar Therapeutics Inc. stock go up soonAI Pattern Recognition and Trade Prediction - Newser
Monopar Therapeutics Inc. stock trendline breakdownRisk Managed Watchlist with Breakout Picks - Newser
Applying Elliott Wave Theory to Monopar Therapeutics Inc.Watchlist Summary for Active Day Traders - Newser
Chart based exit strategy for Monopar Therapeutics Inc.Free Strong Buy With Technical Confidence - Newser
Is it too late to sell Monopar Therapeutics Inc.Investment Roadmap for High Potential Stocks - Newser
How Monopar Therapeutics Inc. stock performs during market volatilityStock Price Prediction Using AI Tools - Newser
How to monitor Monopar Therapeutics Inc. with trend dashboardsStock Holding Strategy Long-Term Summary Sheet - Newser
Does Monopar Therapeutics Inc. qualify in momentum factor screeningShort-Term Stock Trend Forecast Guide - Newser
Can swing trading help recover from Monopar Therapeutics Inc. lossesSmart Entry Watchlist with Daily Analysis - Newser
What momentum shifts mean for FWONAPattern Breakout Prediction for Short Term - Newser
Is Monopar Therapeutics Inc. showing signs of accumulationShort Term Momentum Based Trading Strategy - Newser
Why Monopar Therapeutics Inc. stock attracts strong analyst attentionFree Fundamental + Technical Hybrid Stock Tips - Newser
Monopar Therapeutics MNPR Q2 2025 Earnings Preview Downside Risk Amid Increased Operating Expenses - AInvest
Monopar Therapeutics Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Forecasting Monopar Therapeutics Inc. price range with options dataPredictable Entry Strategy With Technical Backing - Newser
Is Monopar Therapeutics Inc. a good long term investmentDiscover undervalued stocks before they soar - Jammu Links News
How strong is Monopar Therapeutics Inc. company’s balance sheetBuild a diversified portfolio for steady profits - Jammu Links News
What drives Monopar Therapeutics Inc. stock priceAchieve rapid portfolio appreciation today - Jammu Links News
Is Monopar Therapeutics Inc. a growth stock or a value stockBuild wealth steadily with smart stock selection - Jammu Links News
When is Monopar Therapeutics Inc. stock expected to show significant growthInvest smarter with data-backed trading alerts - Jammu Links News
What are the latest earnings results for Monopar Therapeutics Inc.Capitalize on fast-moving stock opportunities - Jammu Links News
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):